05 December 2012

# **Equity Focus**

### Key Data

Share price (HK\$)	122.7
Target price (HK\$)	NA
Upside potential (%)	NA
52Wk H/L(HK\$)	148.9/ 100.0
Issued shares:	1,142.7
Market cap (HK\$mn)	132,905
30-day avg vol (HK\$mn)	629
Major shareholder (%):	
Hong Kong SAR	5.64
Thornberg Investments	2.61

Source: Company, Bloomberg, ABCI Securities

#### Revenue composition in 2011 (%)

Turnover related revenue	70.6
Non-turnover related revenue	16.8
Investment income	4.9
Other income	7.6

Source: Company

### Share performance (%)

	Absolute	Relative*
1-mth	(6.8)	(6.7)
3-mth	20.2	6.6
6-mth	18.0	(3.7)

Source: Bloomberg

# 1 year price performance



Source: Bloomberg

### Analyst:

Name: Francis Chan Tel: (852) 2147 8311

Email: francischan@abci.com.hk

# HKEx (388 HK) – Unrated

**Diversified Financial Services** 

# Positive stance reiterated post LME transaction

HKEx announced the issuance of 65.7mn new shares at HK\$118 per share on 29 Nov, after the FSA approval on LME transaction. The newly-raised funds reached HK\$7.7bn, on top of the HK\$3.9bn raised through convertible bonds earlier. HKEx will proceed to the integration with LME from early 2013 onwards. We reiterate our positive stance on HKEx, due to the completion of LME transaction, and recovering average daily turnover (ADT) since early Sep.

**Minimal EPS dilution from new shares.** According to our computation, the EPS dilution will be limited to 1-2% for 2012E and 2013E EPS (Bbg cons.). The issuance price of HK\$118 represents 28.5x 2013E PER (EPS at HK\$4.13) and 8.9x 2013E PBV (BVPS at HK\$13.3). We consider such valuation rich and hence yielded minimal dilution to existing shareholders.

**LME to contribute 14.4% of revenue.** Per our analysis, LME may achieve operating revenue of HK\$1.3bn and pretax profits of HK\$500mn in 2013E. Based on Bloomberg consensus, this represents approximately 14.4% of HKEx's revenue and 8.6% of pretax profits post integration. We consider such contribution adequate in the early stage of merger.

**Beneficiary of Quantitative Easing 3 (QE3).** ADT went up significantly from an average of HK\$44bn from Jun to Aug, to HK\$53bn since early Sep. Meanwhile, the aggregate banking balances rose from HK\$140bn in early Sep to HK\$180bn for now in Hong Kong. HKEx has benefitted significantly from the flooding liquidity since the implementation of QE3 in early Sep. As such, the market turns more positive towards HKEx. Its share price jumped 20.2%, outperforming MSCI HK by 7.4ppt, during the period.

**Trading close to historical average valuation.** The stock traded at an average of 28.0x forward PER from 2008 to 2011. Currently, including the impact from LME acquisition, the stock is trading at 29.7x forward PER, which is 0.5 standard deviation higher than historical average. With better liquidity outlook globally, we consider the stock attractive at present.

**Risk factors:** Better/worse-than-expected average daily turnover and trading velocity, better/worse-than-expected development with LME

# **Financial Summary**

r manciai Summai y				
FY ended Dec 31	2008	2009	2010	2011
Revenue (HK\$ mn)	7,549	7,035	7,566	7,855
Chg(YoY)		(6.81)	7.55	3.82
Net profit (HK\$ mn)	5,129	4,704	5,037	5,093
Chg(YoY)		(8.28)	7.08	1.11
ADT (HK\$ mn)	72,052	62,310	69,117	69,503
AD Dev Vol (#)	428,599	395,736	496,091	604,159
EPS (HK\$)	4.75	4.36	4.67	4.72
PER (x)	25.8	28.1	26.3	26.0
BPS (HK\$)	6.76	7.44	8.04	8.48
P/B (x)	18.1	16.5	15.3	14.5
DPS (HK\$)	4.27	3.92	4.19	4.24
Div. yield (%)	3.5	3.2	3.4	3.5

Source: Company, Bloomberg, ABCI Securities

<sup>\*</sup>Relative to MSCI Hong Kong



# **Disclosures**

### **Analyst Certification**

I, Chan Wing Fu (Francis Chan), being the person primarily responsible for the content of this research report, in whole or in part, hereby certify that all of the views expressed in this report accurately reflect my personal view about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. I and/or my associates have no financial interests in relation to the listed company (ies) covered in this report, and I and/or my associates do not serve as officer(s) of the listed company (ies) covered in this report.

### **Definition of equity rating**

Rating	Definition
Buy	Stock return ≥ Market return rate
Hold	Market return $-6\% \le$ Stock return $\le$ Market return rate
Sell	Stock return < Market return – 6%
Hold	<del>-</del>

Stock return is defined as the expected % change of share price plus gross dividend yield over the next 12 months

Market return: 5-year average market return rate from 2007-2011

Time horizon of share price target: 12-month

## Definition of share price risk

Rating	Definition
Very high	2.6 ≤180 day volatility/180 day benchmark index volatility
High	$1.5 \le 180$ day volatility/180 day benchmark index volatility $< 2.6$
Medium	$1.0 \le 180$ day volatility/180 day benchmark index volatility $< 1.5$
Low	180 day volatility/180 day benchmark index volatility < 1.0

We measure share price risk by its volatility relative to volatility of benchmark index. Benchmark index: Hang Seng Index.

Volatility is calculated from the standard deviation of day to day logarithmic historic price change. The 180-day price volatility equals the annualized standard deviation of the relative price change for the 180 most recent trading days closing price.

### **Disclosures of Interests**

ABCI Securities Company Limited and/or its member companies ("ABCI") may pursue financial interests to the companies mentioned in the report.

### **Disclaimers**

This report is for our clients only and is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expresses or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein. This report should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. ABCI Securities Company Limited is under no obligation to update or keep current the information contained herein. ABCI Securities Company Limited relies on information barriers to control the flow of information contained in one or more areas within ABCI Securities Company Limited, into other areas, units, groups or affiliates of ABCI Securities Company Limited. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of ABCI Securities Company Limited as a whole, of which investment banking, sales and trading are a part. The securities described herein may not be



eligible for sale in all jurisdictions or to certain categories of investors. The price and value of the investments referred to in this research and the income from them may fluctuate. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither ABCI Securities Company Limited nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. Additional information will be made available upon request.

### Copyright 2012 ABCI Securities Company Limited

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of ABCI Securities Company Limited.

Office address: ABCI Securities Company Limited, 13/F Fairmont House, 8 Cotton Tree Drive, Central, Hong Kong. Tel: (852) 2868 2183